Stock Ratings / Health Care / NRC / earnings

OABI (38) MXCT (30) ABSI (45) ONMD (29) ⌘ Pro Terminal →

NRC Health (NRC) Next Earnings Date & Expected ±9% Move

$23.49 +0.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $23.45

NRC Health (NRC) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $519.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $23.45 (-0.17%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 11.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRC)Realized 20D OHLCV Swing Band: ±9%

Deterministic 5-Pillar Attribution (65/100 Composite)

🔍 WHY NRC SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 11.5% FCF Margin ($15.7M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (18% of score)

20D Institutional Volume Accumulation (±9% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)

Macro rate sensitivity & RSI-14 (66.7) create a -9 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$20.33-0.9% Next Q

Q2 (-2Q)

Grade C$20.15+8.8% Next Q

Q3 (-1Q)

Grade C+$21.93+7.1% Next Q

Current

Grade C$23.49+1.3% Hist 90D α

Trajectory: C (57) → C (65)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NRC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, NRC faces multiple-compression risk if 44.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 45x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($21.22) or 200D SMA ($19.17) invalidates the momentum regime and cuts Target Base ($24.23) toward Bear Floor ($18.90).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NRC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 65%NO 35%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±9% Swing Band

±$2.11 Expected Swing

MODEL EARNINGS SETUP GAUGE

NRC Quantitative Pre-Earnings Setup: 65/100

Trailing EPS: $0.52 • YoY Revenue Growth: -4%

Model Bullish Setup (65/100)Model Risk Weight (35/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$137.4M	$11.6M	$15.7M	52%
FY 2024	2024-12-31	$143.1M	$24.8M	$19.2M	52%
FY 2023	2023-12-31	$148.6M	$31.0M	$38.1M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating NRC & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on NRC
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NRC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.71%▲ ASCENDING CHANNEL

2026-10-30O $23.64H $24.01L $23.47C $23.49VOL 86.2K

RES: $28.08SUP: $19.92SMA50: $21.22SMA200: $19.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NRC Butterfly Map → + Track NRC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

33.4%/yr Implied 5Y Growth

vs. -4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NRC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NRC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NRC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRC)

Health Care Rank #137 of 1016 ⚔️ OABI vs NRC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NRC vs. OABI, MXCT, ABSI, ONMD)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NRC Health (NRC) ranks #137 by composite RQD confidence (65/100, grade C) and #440 by equity capitalization ($519.6M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NRC ACTIVE NRC Health	C	65/100	44.8x	—	21.0%	+0.09%	$519.6M	Benchmark Subject
OABI OmniAb Inc.	D-	38/100	—	—	-22.6%	-0.95%	$760.4M	/oabi-vs-nrc →
MXCT MaxCyte Inc.	E	30/100	—	96.0%	-27.1%	+1.17%	$178.5M	/mxct-vs-nrc →
ABSI Absci Corporation	D	45/100	—	—	-35.0%	+1.85%	$2.08B	/absi-vs-nrc →
ONMD OneMedNet Corp (Class A)	E	29/100	—	-30.0%	-35.0%	-2.02%	$26.3M	/onmd-vs-nrc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000070487

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NRC Health (NRC) reported GAAP revenue of $137.4M (-4.0% vs. FY2024 revenue of $143.1M , and -7.5% cumulative change since FY2023) , GAAP net income of $11.6M, operating cash flow of $26.4M, and free cash flow of $15.7M (-17.9% YoY). On the balance sheet, NRC closed FY2025 with $134.9M in total assets against $75.0M in total debt (Altman Z-Score: 3.82, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$137.4M	$11.6M	$26.4M	$15.7M	$134.9M	$75.0M
FY2024 (FY)	2024-12-31	$143.1M	$24.8M	$34.6M	$19.2M	$132.5M	$57.9M
FY2023 (FY)	2023-12-31	$148.6M	$31.0M	$38.1M	$38.1M	—	—

3. NRC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NRC Health (NASDAQ: NRC) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $23.49 (+0.09% 1D, market cap $519.6M). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, NRC ranks #137 in composite RQD confidence.

How does NRC compare to OABI and MXCT in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), NRC carries a Roarable C (65/100 RQD), trailing P/E of 44.8x, gross margin of —, and ROIC of 21.0%. By comparison, OABI (OmniAb Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M) and MXCT (MaxCyte Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -27.1%, cap $178.5M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NRC?

Per NRC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000070487), NRC Health generated $137.4M in revenue (-4.0% YoY), $11.6M in net income, and $15.7M in free cash flow against $134.9M in total assets and $75.0M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 45x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NRC trading relative to its 50-day, 200-day, and 52-week technical levels?

NRC last traded at $23.49 (+0.09% on volume of 124,957 shares), positioning the stock +10.70% above its 50-day simple moving average ($21.22) and +22.54% above its 200-day simple moving average ($19.17). Across its 52-week range of $11.74 to $24.40, NRC sits at the 92.8% percentile with a 14-day RSI of 66.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.0% ($21.38 to $25.60).

NRC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is NRC's next earnings date?

Based on SEC filing cadence, NRC Health (NRC)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is NRC stock expected to move on earnings?

Volatility modeling currently projects a ±9% event move for NRC, spanning a range between $21.38 and $25.6.

Direct Sub-Reports: NRC RQD Cockpit NRC 12M Forecast NRC Earnings & Move NRC Dividends & DRIP NRC Insiders & 13F NRC Whale Options NRC Profit Sankey NRC News & Why